Significance of combination of targeted therapy and immunotherapy in conversion therapy of biliary tract cancer.
10.3760/cma.j.cn112139-20220110-00019
- VernacularTitle:靶免联合治疗在胆道恶性肿瘤转化中应用的意义
- Author:
Zhao Hui TANG
1
;
Jia Lu CHEN
1
;
Shen Yang LIU
1
;
Xiao Peng YU
1
;
Huan Jun TONG
1
;
Zhi Wei QUAN
1
Author Information
1. Department of General Surgery, Shanghai Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200092,China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Biliary Tract Neoplasms/surgery*;
Combined Modality Therapy;
Gastrectomy;
Humans;
Immunotherapy;
Tumor Microenvironment
- From:
Chinese Journal of Surgery
2022;60(4):343-350
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancer has insidious onset and high degree of malignancy, and radical resection is often impossible when it is diagnosed.Conversion therapy can achieve tumor downgrading, so that patients who were initially unresectable have a chance to achieve R0 resection.However, due to the high heterogeneity and complex immune microenvironment of biliary tract cancer, conversion therapy is still in the stage of active exploration.As a new type of conversion therapy, combination of targeted therapy and immunotherapy is of great significance to effectively improve the efficiency of conversion therapy.Further exploration of combination mechanism and improvement of immune microenvironment are expected to become the future direction of combination of targeted therapy and immunotherapy.
